Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

A first step towards personalized medicine in osteosarcoma: Pharmacogenetics as predictive marker of outcome after chemotherapy based treatment.

Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HB, Flucke UE, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, Te Loo DM.

Clin Cancer Res. 2015 Mar 31. pii: clincanres.2638.2014. [Epub ahead of print]

PMID:
25829401
2.

TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.

Middelbeek J, Visser D, Henneman L, Kamermans A, Kuipers AJ, Hoogerbrugge PM, Jalink K, van Leeuwen FN.

Oncotarget. 2015 Apr 20;6(11):8760-76.

3.

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.

Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH, Hoogerbrugge PM, Adema GJ.

Cancer Immunol Immunother. 2015 May;64(5):563-72. doi: 10.1007/s00262-015-1663-y. Epub 2015 Feb 17.

4.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW.

PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.

5.

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.

van der Meer LT, Waanders E, Levers M, Venselaar H, Roeleveld D, Boos J, Lanvers C, Brüggemann RJ, Kuiper RP, Hoogerbrugge PM, van Leeuwen FN, te Loo DM.

Blood. 2014 Nov 6;124(19):3027-9. doi: 10.1182/blood-2014-06-582627. No abstract available.

PMID:
25377564
6.

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.

Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V.

PLoS One. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107. eCollection 2014.

7.

HDAC inhibitors and immunotherapy; a double edged sword?

Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ.

Oncotarget. 2014 Aug 30;5(16):6558-72.

8.

The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.

Masurekar A, Fong C, Hussein A, Revesz T, Hoogerbrugge PM, Love S, Ciria C, Parker C, Krishnan S, Saha V.

Blood Cancer J. 2014 Apr 25;4:e203. doi: 10.1038/bcj.2014.26. No abstract available.

9.

Self-perception and quality of life in adolescents during treatment for a primary malignant bone tumour.

van Riel CA, Meijer-van den Bergh EE, Kemps HL, Feuth T, Schreuder HW, Hoogerbrugge PM, De Groot IJ, Mavinkurve-Groothuis AM.

Eur J Oncol Nurs. 2014 Jun;18(3):267-72. doi: 10.1016/j.ejon.2014.01.005. Epub 2014 Mar 18.

PMID:
24656419
10.

Patient reported outcomes in pediatric oncology practice: suggestions for future usage by parents and pediatric oncologists.

Schepers SA, Engelen VE, Haverman L, Caron HN, Hoogerbrugge PM, Kaspers GJ, Egeler RM, Grootenhuis MA.

Pediatr Blood Cancer. 2014 Sep;61(9):1707-10. doi: 10.1002/pbc.25034. Epub 2014 Mar 20.

PMID:
24648289
11.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

PMID:
24038106
12.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

13.

Adequate endocrine and cardiovascular response to social stress in survivors of childhood acute lymphoblastic leukemia.

Gordijn MS, Gemke RJ, Bierings MB, Hoogerbrugge PM, Tersteeg-Kamperman MD, Heijnen CJ, Rotteveel J, Kaspers GJ.

Psychoneuroendocrinology. 2013 Dec;38(12):3145-9. doi: 10.1016/j.psyneuen.2013.07.013. Epub 2013 Aug 5.

PMID:
23972944
14.

The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer.

Hagleitner MM, Coenen MJ, Aplenc R, Patiño-Garcia A, Chiusolo P, Gemmati D, De Mattei M, Ongaro A, Krajinovic M, Hoogerbrugge PM, Vermeulen SH, te Loo DM.

Pharmacogenomics J. 2014 Apr;14(2):115-9. doi: 10.1038/tpj.2013.19. Epub 2013 May 7.

PMID:
23648444
15.

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.

Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.

PMID:
23407458
16.

Absolute lymphocyte count predicts the response to new influenza virus H1N1 vaccination in pediatric cancer patients.

Mavinkurve-Groothuis AM, van der Flier M, Stelma F, van Leer-Buter C, Preijers FW, Hoogerbrugge PM.

Clin Vaccine Immunol. 2013 Jan;20(1):118-21. doi: 10.1128/CVI.00585-12. Epub 2012 Nov 21.

17.

Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.

Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, de Korte CL, Kapusta L.

Eur Heart J Cardiovasc Imaging. 2013 Jun;14(6):562-9. doi: 10.1093/ehjci/jes217. Epub 2012 Oct 29.

PMID:
23109647
18.

Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia.

Gordijn MS, van Litsenburg RR, Gemke RJ, Huisman J, Bierings MB, Hoogerbrugge PM, Kaspers GJ.

Pediatr Blood Cancer. 2013 Mar;60(3):479-85. doi: 10.1002/pbc.24261. Epub 2012 Aug 8.

PMID:
22887764
19.

Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy controls.

Gordijn MS, van Litsenburg RR, Gemke RJ, Bierings MB, Hoogerbrugge PM, van de Ven PM, Heijnen CJ, Kaspers GJ.

Psychoneuroendocrinology. 2012 Sep;37(9):1448-56. doi: 10.1016/j.psyneuen.2012.01.014. Epub 2012 Mar 2.

PMID:
22385687
20.

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN, Kuiper RP.

PLoS Genet. 2012;8(2):e1002533. doi: 10.1371/journal.pgen.1002533. Epub 2012 Feb 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk